RE: Halted....Look to see reason2007 14:15 ET 'Noveko International Inc. gets the green light to market its antimicrobial face masks in Canada ' - CNW
Health Canada issues establishment licence to Noveko Inc.
------------------------------------------------------------------------
(EKO-TSX Venture Exchange)
MONTREAL, Aug. 28 /CNW Telbec/ - NOVEKO INTERNATIONAL INC. ("Noveko" or
"the Company") announces that its subsidiary Noveko Inc. has been granted an
establishment licence by Health Canada and can now begin marketing its 3xEZ
(surgical mask) and its 5dEZR (surgical respirator) face masks in Canada.
These face masks are derivative products from Noveko's patented
antimicrobial technology and provide 100% bioprotection (superior to
N-99-approved products), while facilitating breathing and offering more
comfortable skin contact than any other face mask currently on the market.
"We are very pleased that Health Canada has issued an establishment
licence to our subsidiary Noveko Inc., thereby kickstarting the marketing of
our antimicrobial face masks for health institutions (hospitals, medical
clinics, dental clinics, etc.), medical bodies, government organizations,
civil relief units and the general public, notably in the event of pandemics
considering our face masks' superior protection," indicated Alain Bolduc,
President and Chief Operating Officer of Noveko.
Mr. Bolduc specified that: "Noveko Inc. has already set up its complete
face mask production chain through Canadian, U.S. and Asian companies.
Furthermore, Noveko has sufficient inventory to shortly launch its
antimicrobial face masks on the Canadian market."
The North American mask market represents annual sales of approximately
US$800 million, of which the Canadian market accounts for some US$200 million,
and the global market totals approximately US$8 billion. With its unique
antimicrobial technology, which has given rise to a new generation of face
masks providing the necessary protection against bacteria and viruses and
contributing to prevent pandemics, Noveko Inc. intends to become an active
player in this market. It will do so through medical product distribution
networks, by setting up a sales force and by entering into alliances with
manufacturers. Noveko Inc. is also targeting other geographic markets,
including the United States, various Asian and Eurasian markets, Europe and
Africa. In addition to the U.S. patent delivered by the United States Patent
and Trademark Office (May 2006), Noveko's antimicrobial technology has been
patented by the Eurasian Patent Office, located in Moscow (July 2007), and the
Company has similar international patents pending.
Profile of Noveko International Inc.
------------------------------------
Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. (BLI). ECM
specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (antimicrobial
face masks and air filters). SyMa specializes in the manufacture of
sanitizers, more specifically the antimicrobial products (for hands, feet and
surfaces) sold under the Azuro trademark. For its part, BLI specializes in the
custom processing and distribution of steel products based on client
specifications and designs. It has also developed and markets a line of
downdraft particle extraction tables for various industrial, commercial and
pharmaceutical markets. Operating since September 2002, the Company was listed
on the TSX Venture Exchange on February 3, 2004.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information: Andre Leroux, Chairman of the Board and Chief
Executive Officer, (514) 344-3030; Alain Bolduc, President and Chief Operating
Officer, (514) 344-3030, https://www.noveko.com; Marie-Claude Leroux, Morin
Public Relations, (514) 289-8688, ext. 224, Cell: (514) 705-5897,
marieclaude@morinrp.com